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Abstract
Background:  Myocardial hypoxic-ischemic injury is the cause of significant morbidity and
mortality worldwide. The cardiomyocyte response to hypoxic-ischemic injury is known to include
changes in cell cycle regulators. The cyclin-dependent kinase inhibitor p57Kip2 is involved in cell
cycle control, differentiation, stress signaling and apoptosis. In contrast to other cyclin-dependent
kinase inhibitors, p57Kip2 expression diminishes during postnatal life and is reactivated in the adult
heart under conditions of cardiac stress. Overexpression of p57Kip2 has been previously shown to
prevent apoptotic cell death in vitro by inhibiting stress-activated kinases. Therefore, we
hypothesized that p57Kip2 has a protective role in cardiomyocytes under hypoxic conditions. To
investigate this hypothesis, we created a transgenic mouse (R26loxpTA-p57k/+) that expresses
p57Kip2 specifically in cardiac tissue under the ventricular cardiomyocyte promoter Mlc2v.
Results: Transgenic mice with cardiac specific overexpression of p57Kip2 are viable, fertile and
normally active and their hearts are morphologically indistinguishable from the control hearts and
have similar heart weight/body weight ratio. The baseline functional parameters, including left
ventricular systolic pressure (LVSP), left ventricular end diastolic pressure (LVEDP), LVdp/dtmax,
heart rate (HR) and rate pressure product (RPR) were not significantly different between the
different groups as assessed by the Langendorff perfused heart preparation. However, after
subjecting the heart ex vivo to 30 minutes of ischemia-reperfusion injury, the p57Kip2 overexpressing
hearts demonstrated preserved cardiac function compared to control mice with higher left
ventricular developed pressure (63 ± 15 vs 30 ± 6 mmHg, p = 0.05), rate pressure product (22.8
± 4.86 vs 10.4 ± 2.1 × 103bpm × mmHg, p < 0.05) and coronary flow (3.5 ± 0.5 vs 2.38 ± 0.24 ml/
min, p <0.05).
Conclusion:  These data suggest that forced cardiac expression of p57Kip2 does not affect
myocardial growth, differentiation and baseline function but attenuates injury from ischemia-
reperfusion in the adult mouse heart.
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Background
Ischemic heart disease is the leading cause of morbidity
and mortality in the industrialized world, but the devel-
opment of effective therapy has been hampered by the
lack of mechanistic insights into the physiological
response of the heart to hypoxic stress. Adult cardiomyo-
cytes respond to hypoxic stress by reverting to genetic pro-
grams associated with embryonic cardiac development,
collectively referred to as "the fetal gene program" [1].
One of the most critical factors controlling heart growth
and development is intrauterine oxygen availability [2,3].
Embryonic cardiac development occurs in an environ-
ment of low oxygen tension and hypoxia regulates several
stress-related pathways affecting cellular proliferation, dif-
ferentiation and death. While the low oxygen tension at
this stage of development is "physiologic", the genes
whose expression is modulated by differences in oxygen
tension are adapted to the ambient levels of oxygen dur-
ing this period. Recapitulation of this developmental pro-
gram may be a physiologic adaptation that allows the
ischemic heart to respond to hypoxia.
Heart cells divide during development and then exit the
cell cycle as they undergo terminal differentiation [4,5].
This lack of proliferative capacity poses a challenge for
hearts that undergo ischemic injury as they loose cardiac
mass and terminal heart failure frequently results. During
development, cardiomyocytes proliferate extensively.
Cells are driven through the cell cycle by a complex of two
classes of proteins, cyclins and cyclin dependent kinases
(CDKs). This complex is regulated by two families of cyc-
lin-dependent kinase inhibitors (CKIs). The INK4 family
(p16Ink4a, p15Ink4b, p18Ink4c, p19ARF) specifically inhibit
CDK4 and CDK6, while the CIP/KIP family (p21Cip1,
p27Kip1, and p57Kip2) inhibit all G1/S CDKs [6,7]. The
CKIs are implicated in cell cycle exit and terminal differ-
entiation in a number of cell types [8-10]. Of all the CKIs,
only p57Kip2 has been shown to be essential for embryonic
development, as p57Kip2 null mice display significant con-
genital defects such as cleft palate, omphalocele and short
limbs [11-13]. In addition, the p57Kip2-/-  mice exhibit
increased apoptosis in many tissues, including the heart.
They typically die in utero or soon after birth due to aspi-
ration and respiratory insufficiency from the cleft palate
[12,13]. In the mouse heart, p57Kip2 message is up-regu-
lated during mid-gestation [12,14]. The p57Kip2 protein
levels peak during late gestation, and then disappear dur-
ing early fetal life [15]. Low levels of p57Kip2 protein are
present in the adult human heart, which then increase
during terminal heart failure [16]. By contrast, there is a
concomitant decrease in p21Cip1 and p27Kip1 levels [16].
Apart from inhibiting the cell cycle, p57Kip2 has additional
roles in the cell. For example, p57Kip2 modulates stress
activated signaling by functioning as an endogenous
inhibitor of c-Jun kinase (JNK/SAPK), as the QT domain
of p57Kip2 binds and inhibits the JNK/SAPK pro-apoptotic
activity [17]. In addition, p57Kip2 is up-regulated at early
time points of hypoxia [18], indicating it is within the
early wave of hypoxia-responsive genes rather than being
secondarily induced. Previous studies have demonstrated
that p21Cip1 and p27Kip1 overexpression in cultured rat car-
diomyocytes protects the cells from hypoxia-induced
apoptosis, and this protection appears to be independent
of CKI activity [19]. Because p57Kip2 is differentially regu-
lated from the two other CIP/KIP family members during
hypoxic stress, it is plausible that it possesses similar car-
dioprotective properties in this setting and compensates
for the observed downregulation of p21Cip1 and p27Kip1 in
the stressed heart [20]. The possibility that p57Kip2 has a
previously unrecognized role in cardiac biology related to
protection from hypoxic-ischemic injury has not been
examined. We hypothesized that p57Kip2 protects cardio-
myocytes under conditions of limited oxygen supply as
occurs during embryonic cardiac development and in
ischemic injury of the adult heart.
To evaluate this hypothesis, we generated a mouse model
(R26loxpTA-p57k/+) that allows cre-inducible functional
expression of p57Kip2 in a tissue-specific fashion. We used
this transgenic model in combination with the Mlc2v-
Crek/+  transgenic mouse to force myocardial specific
p57Kip2 expression in the embryonic and adult heart [21]
and we show that myocardial specific expression of
p57Kip2 attenuates hypoxic-ischemic injury in the adult
mouse heart. These findings suggest that p57Kip2 may rep-
resent a developmentally regulated protein aiming to pro-
tect cardiomyocytes under conditions of limited oxygen
supply during development and in pathologic ischemic
conditions of adulthood.
Results
Cardiac specific overexpression of p57Kip2 does not affect 
heart development or cardiomyocyte proliferation
Since the p57Kip2 cDNA is preceded by a loxP-flanked
strong transcriptional termination sequence (tpA), in the
absence of cre-recombinase p57Kip2 transcription is termi-
nated prematurely and the generated transgenic mice
(R26loxpTA-p57k/+) were phenotypically normal as
expected. When these mice were crossed with the Mlc2v-
Crek/+ transgenic mice that express cre-recombinase under
the transcriptional control of the myosin light chain-2
ventricular (mlc2v) promoter, the cre-mediated excision of
the floxed termination sequence led to forced expression
of p57Kip2 in ventricular cardiomyocytes. Fifty-three dou-
ble heterozygous animals (R26loxpTA-p57k/+/Mlc2v-Crek/+)
from these crosses have been analyzed. The double trans-
genic mice developed normally and no defects in embryos
or adults were observed. Litter sizes and fertility were sim-
ilar to those of control mice and offspring were producedBMC Physiology 2008, 8:4 http://www.biomedcentral.com/1472-6793/8/4
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in the expected Mendelian ratios (Table 1). None of the
R26loxpTA-p57k/+/Mlc2v-Crek/+ mice were prone to early
lethality over 2 years of observation suggesting that car-
diac specific overexpression of p57Kip2 is well tolerated
from the very early stages of myocardial differentiation.
Ventricular tissue-specific cre-recombination that allows
p57Kip2 over-expression in cardiomyocytes of the com-
pound heterozygous offspring could be detected by PCR
as shown in the diagram (Figure 1A, 1C).
We examined p57Kip2 expression by reverse transcriptase
(RT-PCR) and immunohistochemistry in wild type (WT)
or single (R26loxpTA-p57k/+) transgenic hearts and com-
pared them to the adult double transgenic (R26loxpTA-
p57k/+/Mlc2v-Crek/+)  hearts. RT-PCR analysis demon-
strated the presence of p57Kip2 message in the adult double
transgenic heart, while at the same number of cycles, there
was no visible band in the adult WT or single transgenic
heart (Figure 1D). The average p57Kip2 expression by quan-
titative RT-PCR analysis was found to be 2.7 fold higher in
compound transgenic hearts (data not shown). Taking
into consideration that only 14–20% of adult mouse ven-
tricular cells are cardiomyocytes and the reported success
of recombination is approximately 80% with the Mlc2v-
Cre mouse [21], this result indicates that the cardiomyo-
cytes of the compound transgenic mice express an 8–12
fold higher level of p57Kip2 transcripts above the wild type
control animals [5,21]. Since there may still be some non-
ventricular tissue in this preparation, this number repre-
sents a lower estimate of the efficiency of our transgenic
system at the mRNA level. Immunohistochemistry dem-
onstrated that p57Kip2 is abundantly present in the nuclei
of adult cardiomyocytes in the R26loxpTA-p57k/+;Mlc2v-
Crek/+ transgenic mice (approximately 80% of the cardio-
myocytes nuclei are stained for p57Kip2, whereas it is virtu-
ally absent from the cardiomyocytes of wild-type animals
(Figure 2). We did not observe p57Kip2 expression in the
skeletal muscle or in the liver of the double transgenic ani-
mals (Figure 2F, 2G). These results indicate that the trans-
gene is not only specific and effective in overexpressing
p57Kip2 in cardiomyocytes, but also that the cellular capac-
ity for degradation of p57Kip2 is overcome and not suffi-
cient to reduce the elevated protein levels to normal.
During development, p57Kip2  gene expression is first
observed in the heart of WT mice at E10.5 [14,15]. By
E11.5, p57Kip2 protein is present in the nuclei of the endo-
cardial cells and in about 75% of the WT cardiomyocytes
(Figure 3). In the double transgenic embryos, p57Kip2 was
first detected in cardiomyocyte nuclei at E9.5, following
the expression of Mlc2v-Cre during early myocardial dif-
ferentiation [22], indicating that p57Kip2  expression is
directed by the Mlc2v promoter (Figure 3D).
Table 1: Genotype analysis of offspring resulting from R26loxp-
TAp57k/+;Mlc2v-crek/+crosses.
Genotype
n = 203
R26loxp-TAp57k/k;Mlc2v-crek/+ 13
R26loxp-TAp57k/k;Mlc2v-cre+/+ 21
R26loxp-TAp57k/+;Mlc2v-crek/+ 53
R26loxp-TAp57k/+;Mlc2v-cre+/+ 50
R26loxp-TAp57+/+;Mlc2v-crek/+ 25
R26loxp-TAp57+/+;Mlc2v-cre+/+ (WT) 41
The R26loxp-TAp57k/+;Mlc2v-crek/+ genotype is represented in the 
expected Mendelian ratio in the offspring. However, mice with p57KIP2 
cardiac-specific overexpression that are homozygous for the R26p57 
allele (R26loxp-TAp57k/k;Mlc2v-crek/+) are significantly under-
represented in the offspring (p < 0.01 by Chi-square and n = 203)
Creation of a transgenic mouse with forced expression of p57Kip2 in a cre dependent manner Figure 1
Creation of a transgenic mouse with forced expression of p57Kip2 in a cre dependent manner. (A) Recombination 
scheme displaying the structure of the targeting vector, genomic R26 locus, targeted locus after homologous recombination 
and recombined locus after cre activation (B) PCR genotype analysis of tail genomic DNA (gDNA) (C) PCR analysis shows 
that cre-induced recombination is restricted to the heart, and occurs only in the presence of cre recombinase. T= tail gDNA, H 
= heart gDNA (D) RT-PCR analysis demonstrates robust expression of p57Kip2 message in adult transgenic hearts in the pres-
ence of cre recombinase, compared to barely detectable levels in the absence of cre recombinase.BMC Physiology 2008, 8:4 http://www.biomedcentral.com/1472-6793/8/4
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Gross cardiac defects and histological evidence of ven-
tricular thinning, hypertrophy, or fibrosis were absent in
adult p57Kip2 overexpressing hearts. Similarly, the ratio of
heart weight to body weight (HW/BW) of the transgenic
hearts did not significantly differ from that of wild type
animals (6.6 × 10-3 ± 0.2 × 10-3, m ± SEM, n = 8 vs. 7.5 ×
10-3 ± 0.7 × 10-3, n = 4) at 3 months of age. There was also
no difference in the rate of apoptosis at this age as deter-
mined by TUNEL assay (data not shown). To assess
whether cardiomyocyte-specific p57Kip2  overexpression
affects cardiomyocyte proliferation we performed
immunofluorescence experiments with Ki-67 antibody, a
marker for DNA synthesis and cell cycling in E8.5-E11.5
hearts [23]. We did not detect any difference in the
number of Ki-67 positive cardiomyocytes between p57Kip2
overexpressing transgenic and control animals (Figure 3).
p57Kip2protein is expressed specifically in the adult transgenic mouse heart Figure 2
p57Kip2 protein is expressed specifically in the adult transgenic mouse heart. p57Kip2 expressed in the hearts of adult 
R26loxpTA-p57k/+;Mlc2v-Cre+/- mice (B, E), while it is absent from WT hearts (A, D). p57Kip2 expression is restricted to the 
hearts of transgenic animals and is absent from adult muscle (C) and liver (F).BMC Physiology 2008, 8:4 http://www.biomedcentral.com/1472-6793/8/4
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These results indicate that p57Kip2 overexpression does not
affect the ability of cardiomyocytes to enter S-phase. Inter-
estingly, in some of the cells, p57Kip2 and Ki-67 immuno-
reactivity was present in the same nucleus, although they
appeared in mutually exclusive nuclear areas (Figure 3G–
I). Such cells were found in both transgenic and control
animals and therefore cannot be attributed to a transgene
effect. This is in accordance with the pattern of p57Kip2
expression described in trophoblast giant cells, in which
BrdU and p57Kip2 co-immunoreactivity could be detected
after the cells committed to endoreduplication [24].
Endoreduplication is a process of repeated rounds of DNA
synthesis in the absence of mitosis, which occurs in both
trophoblast cells and cardiomyocytes and results in the
formation of polyploid cells. Thus, it is possible that in
cardiomyocytes, p57Kip2 expression and terminal differen-
tiation are not associated with cell cycle exit but rather
with endoreduplication.
Forced p57Kip2 expression in the embryonic heart does not impair cardiomyocyte proliferation Figure 3
Forced p57Kip2 expression in the embryonic heart does not impair cardiomyocyte proliferation. Localization of 
p57Kip2 and Ki-67 in ventricular cardiomyocytes of E9.5 wild type (WT) and R26loxpTA-p57k/+;Mlc2v-Crek/+ animals by indirect 
immunofluorescence. In WT E9.5 cardiomyocytes p57Kip2 is not yet expressed (A-C). However, p57Kip2 is expressed in most 
cardiomyocytes of the R26loxpTA-p57k/+;Mlc2v-Cre+/- mouse embryos as early as E9.5 (D-F). Expression of p57Kip2 in embryonic 
cardiomyocytes does not preclude Ki-67 expression (E, F). DNA synthesis in the heart of R26loxpTA-p57k/+;Mlc2v-Crek/+ trans-
genic mice is similar to the hearts of wild type animals despite the abundance of p57Kip2 protein in the cardiomyocytes of the 
transgenic hearts. In the merged pictures (third column), the yellow nuclei represent cardiomyocytes co-labeled by both anti-
bodies. High power magnification of the same cardiomyocyte labeled with both antibodies, illustrates that although there are 
many cells stained with both p57Kip2 and Ki-67, in most cells p57Kip2 and Ki-67 immunoreactivity occur in exclusive nuclear 
domains (G, H, I).BMC Physiology 2008, 8:4 http://www.biomedcentral.com/1472-6793/8/4
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p57Kip2 expression in adult cardiomyocytes protects hearts 
from ischemia/reperfusion injury
After we characterized histologically the adult transgenic
mice and demonstrated no differences in 3 months of age,
we proceeded with the analysis of cardiovascular func-
tion. We studied age matched adult mice from the same
cohort that covered the adult lifespan from 14–30 weeks,
when the excitation-coupling mechanisms are known to
remain constant [25]. To assess the contractile function of
p57Kip2 overexpressing transgenic hearts, we utilized the
p57Kip2 protects hearts from ischemia/reperfusion (I/R) injury in the Langendorff isolated perfused heart model Figure 4
p57Kip2 protects hearts from ischemia/reperfusion (I/R) injury in the Langendorff isolated perfused heart 
model. Upper Panel: Representative hemodynamic tracings from Langendorff isolated perfused heart from a control and a 
R26loxpTA-p57k/+;Mlc2v-Crek/+ animal. Real-time condensed recordings of hemodynamic parameters (LVP=left ventricular pres-
sure, LVSP=left ventricular systolic pressure, LVEDP=left ventricular end diastolic pressure, dp/dt(max/min) and HR) are shown. 
Lower Panel: Representative sections of a control (left) and a R26loxpTA-p57k/+;Mlc-2v+/- (right) heart. The hearts were sliced 
into sections and stained with 2,3,5-TTC followed by formalin fixation. Viable tissue is stained brick red, while infarcted areas 
are white. Note the more significant necrotic area (black arrow) in the injured, control heart.BMC Physiology 2008, 8:4 http://www.biomedcentral.com/1472-6793/8/4
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Langendorff isolated perfused mouse heart preparation as
previously described [26-28]. After 30 minutes of stabili-
zation baseline functional data were obtained and the
hearts were then subjected to a protocol of 30 minutes
global ischemia followed by 30 minutes reperfusion. This
protocol is based on our experience from previous studies
[26-28]. In one of the experiments we assessed the myo-
cardial necrotic area after staining with 10% 2,3,5-triphe-
nyltetrazolium chloride (TTC) and we found that the area
of necrotic tissue was reduced (20% vs. 37%) in the dou-
ble transgenic heart compared with the control (Figure 4).
The baseline functional parameters, including left ven-
tricular systolic pressure (LVSP), left ventricular end
diastolic pressure (LVEDP), LVdp/dt, rate pressure prod-
uct (RPP) and heart rate (HR) were not significantly differ-
ent between the different groups. However, after
subjecting the hearts to 30 minutes of ischemia, the reper-
fused p57Kip2 expressing hearts exhibited significantly bet-
ter preservation of cardiac function than the WT hearts.
More specifically the transgenic hearts demonstrated
higher left ventricular developed pressure (LVDP), rate
pressure product (RPP) and coronary flow (CF) as
assessed at the end of the reperfusion period (p ≤ 0.05,
Figure 5; Table 2). The hemodynamic benefits were appar-
ent from the onset of the reperfusion stage and were main-
tained throughout the 30 min period, suggesting that the
protective effect of the p57Kip2 transgene may be manifest
during the acute hypoxic phase and not restricted to the
reperfusion phase of the injury.
p57Kip2-mediated cardioprotection in the ex vivo ischemia 
reperfusion injury is associated with modulation of the 
stress signaling cascade
Since p57Kip2 has been found to physically interact with
and inhibit JNK/SAPK, we investigated whether the cardi-
oprotective effects of p57Kip2 were mediated through mod-
ulation of the JNK stress signaling pathway. We performed
a phospho-proteomic screen that demonstrated wide
ranging changes in the stress signaling cascade. These
included a 28–34% reduction in phosphorylation of the
JNK/SAPK epitopes Y185 and T183 from ischemic p57Kip2
overexpressing hearts compared to similarly ischemic
control hearts after normalization to control for inaccura-
cies in protein determination and sample loading (Figure
6). In addition, phosphorylation changes in other stress
signaling molecules not known to be directly related to
Summary of hemodynamic data from the isolated heart perfusion evaluation of control and p57Kip2 overexpressing mice  (R26loxpTA-p57k/+;Mlc-2vCrek/+), at baseline and post ischemia/reperfusion (I/R) Figure 5
Summary of hemodynamic data from the isolated heart perfusion evaluation of control and p57Kip2 overex-
pressing mice (R26loxpTA-p57k/+;Mlc-2vCrek/+), at baseline and post ischemia/reperfusion (I/R). Left Ventricular 
Systolic Pressure (LVSP), Left Ventricular End Diastolic Pressure (LVEDP), Left Ventricular Developed Pressure (LVDP), Heart 
Rate (HR), Rate Pressure Product (RPP), LVdp/dt(max/min) and Coronary Flow (CF). LVDP, RPP and CF were better conserved 
in the transgenic hearts to a statistical significant degree compared to the hearts of wild type littermates (p < 0.05).BMC Physiology 2008, 8:4 http://www.biomedcentral.com/1472-6793/8/4
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p57Kip2 such as αB-crystallin and heat shock protein 27
(Hsp27), MEK1, MARCKS, Akt1, PKCδ and PKCγ were
also found in this screen.
Discussion
p57Kip2 encodes a maternally expressed cyclin dependent
kinase inhibitor of the CIP/KIP family. While loss of func-
tion studies on p57Kip2 have provided important func-
tional clues, herein we report over-expression experiments
that provide additional insight into its function. For better
understanding of the role of p57Kip2 in the cardiac tissue,
we created a transgenic model that forces expression of
p57Kip2 beyond its narrow temporal window of expres-
sion. In our model, p57Kip2 expression was observed from
early gestation (E9.5) and the tissue-specific pattern per-
sisted into adult life at 2.7 fold higher levels over the wild
type controls. Cardiac specific expression of
p57Kip2beginning at E9.5 did not appear to be deleterious,
as  R26loxpTA-p57k/+;Mlc2v-Crek/+  transgenic mice dis-
played normal cardiac growth both during development
and postnatal life. This is in contrast to the observed
effects of p57Kip2 on other tissues, such as kidney and
brain, that were shown to be sensitive to an even lower
p57Kip2 dosage change in BAC transgenic animals [29]. In
addition, DNA synthesis persisted in the p57Kip2 over-
expressing cardiomyocytes, suggesting that the ability of
cardiomyocytes to enter S-phase remained unimpaired. It
is likely that sufficient amounts of the necessary CDKs are
present in the fetal cardiomyocytes to overcome the
induced excess of p57Kip2. Alternatively, excess p57Kip2
could also have been removed by ubiquitination of the
QT domain and degraded via the proteasome pathway
[30,31]. However, the widely present p57Kip2 protein in
the fetal and adult cardiomyocytes, beyond the spatial
and temporal pattern of endogenous expression, indicates
that the cellular capacity for p57Kip2 degradation was over-
come and not sufficient to normalize the elevated protein
levels. The concurrent expression of p57Kip2 in actively
proliferating cells is intriguing and suggests that, in cardi-
omyocytes, p57Kip2 expression and terminal differentia-
tion are not necessarily associated with cell cycle exit but
rather with endoreduplication as in trophoblasts [24].
In our studies, we found that forced expression of p57Kip2
in the adult heart was associated with a protective effect
when the heart undergoes injury by transient ischemia/
reperfusion. It seems unlikely that the cell cycle inhibitory
function of p57Kip2 is a factor in this process, as the protec-
tive effect was immediate. An alternative explanation to
consider is the improved coronary flow in the transgenic
hearts. Ischemia and reperfusion significantly increase tis-
sue edema in the injured myocardium with secondary
Table 2: Description of experimental animals and cardiac functional parameters
Control R26loxp-TAp57k/+; Mlc2v-crek/+
n = 6 n = 4
Age (days old) 136 ± 22 133 ± 23
Body Weight (grams) 32 ± 1 34.2 ± 1
Heart Weight (mg) 162 ± 2 214 ± 2
Heart/Body Weight Ratio (mg/g) 5.03 ± 0.45 6.19 ± 0.75
Baseline functional parameters
LVSP (mmHg) 97 ± 9 107 ± 3
LVEDP (mmHg) 3.4 ± 1.4 2 ± 1
LVDP (mmHg) 94 ± 10 105 ± 3
HR (bpm) 418 ± 22 387 ± 24
RPP (bpm × mmHg) 37,920 ± 3,064 41,218 ± 2,794
dP/dt max (mmHg/sec) 2,461 ± 262 2,764 ± 180
CF (ml/min) 4.53 ± 0.24 4.58 ± 0.26
Functional Parameters post I/R
LVSP (mmHg) 75 ± 3.5 87 ± 11
LVEDP (mmHg) 39 ± 4.3 23 ± 8
LVDP (mmHg) 30 ± 6* 63 ± 15*
HR (bpm) 362 ± 37 368 ± 17
RPP (bpm × mmHg) 10,361 ± 2,077** 22,787 ± 4,858**
dP/dt max (mmHg/sec) 944 ± 193 1,513 ± 332
CF (ml/min) 2.38 ± 0.24** 3.5 ± 0.5**
Values are means ± SE. The two asterisks (**) indicate statistical significance with a probability of p < 0.05 (unpaired t-test), while the one asterisk 
indicates a probability of p = 0.05. One-way ANOVA followed by Fisher post hoc test also indicated significant difference among these groups. There 
was also a strong trend for lower LVEDP in the transgenic hearts; however with the small number of tested animals this did not reach statistical 
significance. LVSP, left ventricular systolic pressure; LVEDP, left ventricular end diastolic pressure; LVDP, left ventricular developed pressure, HR, 
heart rate; RPP, rate pressure product; CF, coronary flow.BMC Physiology 2008, 8:4 http://www.biomedcentral.com/1472-6793/8/4
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compromise of the regional coronary flow [32]. Since the
p57Kip2 transgene expression is restricted in cardiomyo-
cytes and not present in smooth muscle or endothelial
cells, we believe that the preservation of coronary flow is
rather secondary to the decreased tissue edema in the
transgenic hearts than a primary improvement in coro-
nary vascular flow. Instead, it is more plausible that a sep-
arate function of p57Kip2 leads to cardiac protection in the
hypoxic phase of I/R injury. Our experiments support the
possibility that p57Kip2  modulates the stress signaling
response after ischemia-reperfusion challenge. For exam-
ple, we observed lower levels of JNK activity in the p57Kip2
overexpressing mice. p57Kip2  was shown to modulate
stress-activated signaling and apoptosis by inhibiting c-
Jun amino-terminal kinase/stress-activated protein kinase
(JNK/SAPK) in cultured human embryonic kidney cells,
embryonic fibroblasts and myoblasts [17]. JNK is acti-
vated following ischemia/reperfusion injury, and when
the kinase activity is repressed, the area of infarct damage
is diminished [33]. However, phosphorylation alterations
were not restricted to the JNK/MAPK but involved other
stress signaling molecules not known to be directly related
to p57Kip2 such as crystalline aB and heat shock protein 27
(Hsp27), MEK1, MARCKS, Akt1, PKCδ and PKCγ. While
activation of some of these proteins is reported to be pro-
tective in cardiac disease (heat shock proteins), genetic
and pharmacologic manipulation of some others such as
JNK/MAPK, Akt1 and PKC has been reported to have con-
flicting or unknown roles, with both protective and detri-
mental ramifications for cardiomyocytes after in vitro and
in vivo hypoxic injury [34-39]. Although, the mechanism
for these phosphorylation changes is not known at this
point, these data support the possibility that the p57Kip2-
mediated cardioprotection is associated with wide
changes of the stress signaling cascade. These findings
indicate that p57Kip2 protein may be a converging point
for the regulation of cellular stress, cell proliferation and
apoptosis.
Studies from human patients with both acute and end-
stage heart failure reveal that CKIs revert to a fetal pattern
of expression, i.e., p21Cip1and p27Kip1  decline, while
p57Kip2 is significantly increased [16]. In addition, a recent
analysis of the transcriptional regulation of the human
proximal tubular epithelial cell response to hypoxia iden-
tified p57Kip2 among a tightly regulated cluster of 48 genes
that demonstrated time-dependent up-regulation in
response to hypoxia and a distinct down-regulation upon
reoxygenation [18]. Significantly, p57Kip2 was up-regulated
at early time points of hypoxia indicating it was within the
early wave of hypoxia-responsive genes rather than being
secondarily induced [18]. p57Kip2  is normally highly
expressed in the heart during midgestation, a time when
the coronary arteries are not yet connected to the aortic
root and the fetal heart grows in a low oxygen tension
environment. These observations suggest a protective role
for p57Kip2 under conditions of limited oxygen supply.
Our results provide additional support for this protective
role of p57Kip2 in the setting of hypoxia by demonstrating
that persistent expression of p57Kip2 in cardiomyocytes
attenuates the ischemia-reperfusion injury in the adult
mouse heart.
p57Kip2 over-expression has been reported by us and other
investigators in two independent mouse models of thin
myocardium, one resulting from mutation of the Pax3
transcription factor (Splotch) [14] and the other from dele-
tion of the secreted factor Bmp10 [40]. This phenotype was
associated with a reduction in cardiomyocyte proliferative
activity, while there was no evidence of increased apopto-
sis. These findings are consistent with early suppression of
cardiomyocyte replication and increased differentiation
associated with enhanced activity of p57Kip2 in the mutant
mouse hearts. The mechanism for p57Kip2 up-regulation in
these two models remains unknown, but given the differ-
ent nature of their genetic defects, a direct transcriptional
regulation is unlikely to be involved. An alternative expla-
nation for this finding could be that p57Kip2 up-regulation
represents a secondary, adaptation type of response, or a
selective survival of the p57Kip2 expressing cardiomyocytes
p57Kip2-mediated cardioprotection in the ex vivo ischemia- reperfusion injury is associated with modulation of the stress  signaling response Figure 6
p57Kip2-mediated cardioprotection in the ex vivo 
ischemia-reperfusion injury is associated with modu-
lation of the stress signaling response. Phospho-site 
screen analysis of key stress signaling molecules was per-
formed by standardized densitometric quantification of 
Western immunoblots by KinexusTm Bioinformatics Corpora-
tion (Vancouver, Canada). The graph includes stress signaling 
molecules that display a significant difference between trans-
genic and control hearts.BMC Physiology 2008, 8:4 http://www.biomedcentral.com/1472-6793/8/4
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under conditions of increased stress imposed on the
developmentally impaired thin myocardial wall.
Conclusion
We have generated a transgenic mouse model that allows
specific forced expression of p57Kip2 in cardiomyocytes.
The forced expression of p57Kip2 in cardiomyocytes did
not affect heart development, growth or baseline cardiac
function. However, the continuous presence of p57Kip2 in
the adult mouse heart results in resistance to myocardial
ischemia/reperfusion injury and improved recovery of
cardiac function. Preservation of myocardiac function
after ischemia/reperfusion depends on critical adaptive
responses of the stress signaling network. In the case of
p57Kip2 overexpression, the exact mechanism of this cardi-
oprotection has not been fully elucidated, but it was asso-
ciated with wide range modulations of proteins in stress
signaling pathways. It is conceivable that p57Kip2 is part of
the pre-conditioning process that protects the myocar-
dium from ischemia-reperfusion injury and may consti-
tute a new therapeutic target for ischemic cardiac disease.
As hypoxic stress contributes to many biological disor-
ders, p57Kip2 may be of general physiological importance
for controlling cell proliferation and death under condi-
tions of limited oxygen availability during embryonic car-
diac development and pathologic ischemic conditions of
adulthood. Comparison of the physiological state of
embryonic development with pathologic conditions of
cardiac stress in adulthood, suggests that in adult cardio-
myocytes, the genetic response to stress is to revert to the
expression of fetal genetic patterns associated with embry-
onic cardiac development. p57Kip2 appears to be one of
these fetal genes, which re-emerges under conditions of
hypoxic/ischemic stress. Thus, the hypoxic developmental
history may provide a useful insight in the adult heart's
genetic response to ischemia, by the redeployment of
genes that were adapted to the low oxygen tension charac-
teristic of the fetal/embryonic environment.
Methods
Mice
A gene-targeting vector was constructed using a ROSA26
targeting vector (pROSA26PA) [41]. A 1.4 kb cDNA con-
taining the complete open reading frame of mouse p57Kip2
(generously provided by S. Elledge) was inserted into the
pBigT vector [41] downstream to a loxP-flanked transcrip-
tional termination sequence (tpA). This fragment was
then inserted into the pROSA26PA plasmid [41,42] to cre-
ate the targeting vector, now designated R26loxp-TAp57
(Figure 1). The R26loxp-TAp57 plasmid was electroporated
into AB2.2 mouse embryonic stem (ES) cells and success-
ful homologous recombination was determined by PCR
analysis and confirmed by Southern blotting. The primers
used were: ROSA26FL  5'-CCTAAAGAAGAGGCTGT-
GCTTTGG-3'  and  ROSA26SA 5'-CATCAAGGAAACCCT-
GGACTACTG-3'.
Two separate R26loxp-TAp57  harboring ES clones were
injected into C57BL/6-Tyrc-Brd blastocysts and implanted
into pseudo-pregnant females for the generation of chi-
meras. The male chimeras were mated with C57BL/6-Tyrc-
Brd to obtain F1 progeny. Eight animals with germline
transmitted alleles were derived from two independently
targeted ES cell lines. These mice were designated as
R26loxpTA-p57k/+. R26loxpTA-p57k/+ mice were bred with
knock-in mice carrying the Cre-recombinase  gene under
control of the endogenous mouse Mlc2v promoter (gener-
ously provided by J. Chen, UCSD) to induce myocardial
specific expression of p57Kip2. Mice were bred on a mixed
C57BL/6 or 129/Sv background and were genotyped
using tail extracted genomic DNA for diagnostic PCR
amplification (Figure 1C).
Mice were evaluated by genomic DNA analysis at 3 weeks
and at the time of their sacrifice (14–18 weeks). To detect
the various alleles (ROSA wild-type:1.2 kb, transgenic: 6
Kb, or recombinant transgenic allele: 3.3 kb) we used the
primers  ROSAFORW 5'-CTCCTCAGAGAGCCTCG-
GCTAGGTAGGGGATC-3' and ROSAREV 5'-GGGCGTT-
GTCCTGCAGGGGAATTGAACAGGTG-3. The inserted
p57Kip2 was not expressed unless cre-mediated recombina-
tion removed the transcriptional termination sequence. A
proofreading Taq polymerase for long transcripts (LA
Taq™ DNA Polymerase, TAKARA Mirus Inc, Japan) was
used with the following PCR protocol: 94°C for 1 min,
followed by 30 cycles of 94°C for 30 sec and annealing/
extension at 67°C for 6 min and 10 minutes extension at
72°C. The cre allele (300 bp) was detected by PCR using
the primers CREFORW 5'-GTTCGCAAGAACCTGAT-
GGACA-3'  and  CREREV 5'-CTAGAGCCTGTTTT-
GCACGTTC-3'.
Experiments were performed according to guidelines from
the National Institutes of Health and with an approved
protocol from the Animal Care and Use Committee.
Histological analysis
Mouse tissues and embryos were fixed with 2% PFA over-
night, dehydrated, embedded in paraffin, and sectioned at
5 µm thickness. Primary antibodies included anti-p57Kip2
(Ab-4058, Abcam inc. Cambridge, MA; H-91, Santa Cruz
BioTechnologies, Santa Cruz, CA) at 1:50, Ki-67 (550609,
BD Pharmingen, San Jose, CA) at 1:50, and anti-MHC
(MF-20, from DHSB, University of Iowa) at 1:150. Sec-
ondary detection occurred by fluorescence with the anti-
rabbit Cy3 (Jackson Immunoresearch, West Grove, PA) or
anti-mouse Alexa 488 (Molecular Probes, Eugene, OR) at
1:200 and mounted in media containing DAPI (Vectash-
ield, Vector Laboratories, Burlingame, CA). For immuno-BMC Physiology 2008, 8:4 http://www.biomedcentral.com/1472-6793/8/4
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histochemistry, a biotinylated anti-rabbit antibody was
used at 1:200 and developed using the ABC-DAB system
(Vector Laboratories). Slides were counterstained with
Methylene Blue and mounted in Permount.
RT-PCR
Total RNA was isolated from control and mutant adult
hearts by Trizol (Invitrogen, Carlsbad, CA) extraction. The
PCR reactions were performed with the 7500 RT-PCR sys-
tem (Applied Biosystems, Foster City, CA) using Brilliant
SYBR Green QRT-PCR Master Mix (Stratagene, La Jolla,
CA) and the housekeeping gene β-actin for internal nor-
malization. All samples were tested in triplicates for each
genotype and the results represent averages of individual
experiments.
Langendorff isolated perfused heart and assessment of 
cardiac function
Adult male mice (14–30 weeks) were euthanized with an
intraperitoneal injection of pentobarbital sodium. Hearts
were rapidly excised and arrested in ice-cold Krebs-Hense-
leit buffer, which was constantly gassed with 95% O2 and
5% CO2 to give a pH of 7.4 at 37°C. The buffer was per-
fused at a constant pressure of 55 mm Hg in the non-recir-
culating Langendorff mode as previously described [28].
Briefly, the hearts were cannulated via the ascending aorta
for retrograde perfusion. A left atrial incision was made to
expose the mitral annulus, through which a water-filled
latex balloon was passed into the LV. The balloon was
attached to a pressure transducer, which was connected to
an A/D Converter. The converter transmits the data to a
computer running a cardiovascular data acquisition soft-
ware and recording system (Biopac, MP 100). The LV bal-
loon was inflated to adjust the LV end-diastolic pressure
(LVEDP) to ≈ 10 mm Hg. Myocardial function was meas-
ured at multiple, independent end points. The following
functional parameters were monitored and constantly
recorded: left ventricular developed pressure (LVDP),
which is the difference of left ventricular end systolic pres-
sure (LVESP) minus left ventricular end-diastolic pressure
(LVEDP), heart rate, coronary flow (CF), the maximum
positive or negative first derivative of left ventricular pres-
sure (± dP/dtmax/min) (as index of inotropic and relaxation
state respectively), and the rate pressure product
(RPP=LVDPXHR) was calculated and used as index of car-
diac work and indirect measure of myocardial oxygen uti-
lization (VO2).
Protein extraction and phospho-proteomic screen
Hearts (two from wild type and two from transgenic mice)
were collected after baseline evaluation or after ischemia-
reperfusion ex-vivo injury, snap-frozen in liquid N2 and
stored at -80°C. The frozen hearts were washed with ice-
cold PBS and cut into small pieces in protein lysis buffer
containing 0.5% Triton X-100 and proteinase inhibitors.
Cardiac tissue lysates were prepared by homogenization
and sonication with a Brickmann Polytron homogenizer
and a Fisher Sonic Dismembrator. Protein concentrations
were determined with the bicinchoninic acid assay (BCA™
Protein Assay kit, Pierce, Rockford, IL). The phospho-pro-
teomic screen was performed and analyzed by Kinexus
Inc. (Vancouver, Canada).
Statistical analysis
For parameters that require quantification and evaluation
for statistical significance, results were expressed as mean
± standard error of the mean (SEM). Statistical signifi-
cance (probability values) was determined using the stu-
dent's t-test (two tailed distribution and two sample
unequal variance). For multiple group comparisons, one
way analysis of variance (ANOVA) followed by Fisher post
hoc test was used. A probability of p = 0.05 was considered
to represent statistical significance. Differences in
observed vs expected numbers of a particular genotype
were determined using the Chi-squared test.
Abbreviations
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